Abstract: Methods are provided for producing novel multicellular compositions comprising cancer cells together with pluripotent human stem cells, which are capable of proliferating and differentiating into various normal cell lines and tissue structures. These novel multicellular compositions are useful for investigating the properties of cancer cells in a normal human tissue microenvironment, and for studying interventions that will modulate these properties including devising, testing and screening therapeutic drugs.
Type:
Application
Filed:
May 5, 2004
Publication date:
April 19, 2007
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.
Type:
Application
Filed:
June 9, 2006
Publication date:
December 21, 2006
Applicants:
TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES
Abstract: A method of treating prostate cancer is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of MCP-1 or of an effector thereof, thereby treating the prostate cancer in the subject.
Type:
Application
Filed:
September 12, 2005
Publication date:
August 31, 2006
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders and diseases.
Type:
Application
Filed:
September 29, 2004
Publication date:
August 4, 2005
Applicants:
Technion Research and Development Foundation Ltd., Rappaport Family Institute For Research In The Medical Sciences
Abstract: A method of determining a potential of a diabetic patient to benefit from anti oxidant therapy for treatment of a vascular complication, the method comprising determining a haptoglobin phenotype of the diabetic patient and thereby determining the potential of the diabetic patient to benefit from said anti oxidant therapy, whereby a patient having a haptoglobin 2-2 phenotype benefits from anti oxidant therapy more than a patient having a haptoglobin 1-2 phenotype or a patient having a haptoglobin 1-1 phenotype.
Type:
Application
Filed:
December 31, 2003
Publication date:
November 18, 2004
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: Methods for treating autoimmune diseases are provided. The methods utilize antibodies, antibody fragments or antigenic portions of IGIF or polynucleotides encoding each for inducing protective immunity against the T-cell mediated diseases in individuals having or being predisposed to such diseases.
Type:
Application
Filed:
January 2, 2004
Publication date:
October 28, 2004
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: A method of evaluating a risk of a subject to develop vascular complications is disclosed. The method is effected by determining a haptoglobin phenotype of the subject and thereby evaluating the risk of the subject to develop vascular complications. The risk is decreased in patients with haptoglobin 1-1 phenotype as compared to patients with haptoglobin 1-2 or haptoglobin 2-2 phenotypes.
Type:
Grant
Filed:
October 16, 2000
Date of Patent:
July 29, 2003
Assignee:
Rappaport Family Institute for Research in the Medical
Sciences
Abstract: A method for detecting an interaction between two tester proteins. In a cell incapable of activating a Ras protein, two nucleic acid sequences are expressed. One sequence encodes for a fusion protein comprising a mutant Ras protein incapable of localizing at the cell membrane and not requiring an exchange factor fused to one of the tester proteins. The other sequence encodes for the other tester protein fused to a plasma membrane localization domain. An interaction between the two fusion proteins leads to the expression of a functional Ras protein that is tested as an altered cell phenotype.
Type:
Grant
Filed:
January 22, 2001
Date of Patent:
June 24, 2003
Assignees:
Rappaport Family Institute for Research in the Medical
Sciences, Ami Aronheim
Abstract: Novel haptoglobin derived antioxidants, nucleic acid constructs encoding same, pharmaceutical compositions containing the novel antioxidant or the nucleic acid constructs, and methods of relieving oxidative stress by administration of the antioxidants, the nucleic acid constructs encoding same or the pharmaceutical composition containing same to a subject in need thereof are disclosed.
Type:
Application
Filed:
July 11, 2001
Publication date:
June 19, 2003
Applicant:
Rappaport Family Institute for Research in the Medical Sciences
Abstract: Disclosed are novel human and clam ubiquitin carrier polypeptides involved in the ubiquitination of cyclins A and/or B. Also disclosed are inhibitors of such polypeptides, nucleic acids encoding such polypeptides and inhibitors, antibodies specific for such polypeptides, and methods of their use.
Type:
Grant
Filed:
January 29, 2001
Date of Patent:
March 4, 2003
Assignees:
President and Fellows of Havard College, Rappaport Family Institute for Research in the Medical
Sciences
Inventors:
Joan V. Ruderman, Avram Hershko, Marc W. Kirschner, Fiona Townsley, Alexander Aristarkov, Esther Eytan, Hongtao Yu
Abstract: A method of treating rheumatoid arthritis of an individual is disclosed. The method comprises the step of expressing within the individual at least an immunologically recognizable portion of a cytokine from an exogenous polynucleotide encoding the at least a portion of the cytokine, wherein a level of expression of the at least a portion of the cytokine is sufficient to induce the formation of anti-cytokine immunoglobulins which serve for neutralizing or ameliorating the activity of a respective and/or cross reactive endogenous cytokine, to thereby treat rheumatoid arthritis.
Type:
Grant
Filed:
February 7, 2000
Date of Patent:
July 16, 2002
Assignee:
Rappaport Family Institute for Research in the Medical
Sciences
Abstract: A method for isolating and purifying novel species of E2 ubiquitin-carrier protein, designated E2-F1, is disclosed. A method for preparing enzymatically active fragments of E2-F1 enzyme is also disclosed. The use of purified E2-F1 to produce antibodies is also disclosed. The use of such E2-F1-specific antibodies to detect the presence of E2-F1 in a biological sample, and to inhibit protein degradation are also disclosed. Recombinant DNA molecules which code for E2-F1, and recombinant hosts and vectors which contain E2-F1 coding sequences are also disclosed. The use of such recombinant hosts and vectors to produce E2-F1 protein is also disclosed. The use of purified E2-F1 to identify and to isolate E3 enzyme is also disclosed. Methods for screening substances for the ability to inhibit E2-F1 enzyme activity are also disclosed.
Type:
Grant
Filed:
June 21, 1993
Date of Patent:
January 24, 1995
Assignee:
Rappaport Family Institute for Research in the Medical Sciences
Inventors:
Aaron J. Ciechanover, Nava Blumenfeld, Hedva Gonen